PortViewPortView
Smith & Nephew logo

Smith & Nephew (SNN) Stock Analysis

NYSEHealthcareMedical - Devices

$28.97-0.02%
1-year price historyRange $28.73 – $38.70
52-week range$28.97
$28.56$38.79

What Smith & Nephew does

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Key metrics

Market cap
$12.16B
P/E (TTM)
13.62
EPS (TTM)
$2.13
Beta
0.69
Dividend yield
2.73%
Revenue / share
$15.02
50-day avg
$30.18
200-day avg
$32.07
52-week high
$38.79
52-week low
$28.56
CEO
Deepak S. Nath

ETFs linked to SNN

Broad-market and Healthcare sector ETFs an investor holding Smith & Nephew is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SNN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze SNN in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Smith & Nephew?
Smith & Nephew trades under the ticker SNN on NYSE.
Which exchange is SNN listed on?
SNN is listed on NYSE.
What sector does Smith & Nephew operate in?
Smith & Nephew is classified in the Healthcare sector (Medical - Devices industry).
How can PortView help analyze SNN in a portfolio?
PortView shows SNN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.